The daraxonrasib pancreatic cancer approval by the US Food and Drug Administration has delivered the most striking survival data the field has seen in decades: a twice-daily pill that, in a phase 3 clinical trial, cut the risk of death by 60% and more than doubled median survival in patients whose cancer had progressed after chemotherapy.
Pancreatic cancer remains one of the hardest cancers to treat. Just 3% of patients survive more than five years post-diagnosis, and the standard first-line treatment is gruelling chemotherapy. When that fails, options have historically been limited and largely ineffective. That picture has now changed.
What the trial data shows
The phase 3 clinical trial that informed the FDA’s decision found that patients in the RAS G12 population who received daraxonrasib had a median overall survival of 13.2 months, compared with 6.6 months for those who received chemotherapy, according to Revolution Medicines. That same data showed a 60% reduction in the risk of death across both the RAS G12 and intention-to-treat populations. The FDA moved from receiving the application to granting approval in just 35 days.
The results were presented at the 2026 American Society of Clinical Oncology Annual Meeting, held in Chicago from 29 May to 2 June, according to Let’s Win Pancreatic Cancer. Attending physicians and scientists rose to applaud the presentation, some with tears in their eyes, the New York Times reported.
‘I have not seen anything like that before in trials we have run in pancreatic cancer,’ Dr Brian Wolpin of the Dana-Farber Cancer Institute in Boston, the study’s leader, told the Times. ‘I just kept repeating, “Wow.”‘
How daraxonrasib targets a protein once thought untouchable
The drug works by inhibiting a protein called KRAS, which pancreatic cancer cells depend on to survive. Mutated KRAS proteins are responsible for fuelling more than 90% of pancreatic cancers, and daraxonrasib is the first drug to successfully target them, according to Let’s Win Pancreatic Cancer. For decades, that target appeared out of reach: KRAS has a smooth surface that gives conventional drug molecules almost nothing to bind to.
Daraxonrasib gets around this by gluing other molecules together in such a way that the resulting cluster can grab KRAS and prevent it from reaching the tumour. The mechanism is specific enough that the FDA approved it for use as a second-line treatment in metastatic pancreatic cancer, meaning for patients who have already tried chemotherapy. It is now being evaluated for potential use at earlier stages of the disease.
In rare cases, the drug appears to go further than extending survival. One man in his 70s who enrolled in the daraxonrasib clinical trial in 2022 had seen his cancer spread to his lymph nodes. After taking the drug, his tumours shrank to the point where they are no longer visible on scans, and he remains alive today.
Broader implications for KRAS-inhibiting drugs
The approval of daraxonrasib matters beyond pancreatic cancer. KRAS mutations also drive colon and lung cancers, among others, and the Times reported that dozens of KRAS-inhibiting medications are currently being tested, alone and in combination with chemotherapy and immunotherapy, for their potential across multiple cancer types. The success of daraxonrasib in a phase 3 trial gives that entire field a substantial proof of concept.
Daraxonrasib is manufactured by Revolution Medicines and is described as largely covered by insurance for eligible patients. The drug is taken as a twice-daily pill, which matters for patients already worn down by prior treatment. The clinical burden of advanced pancreatic cancer, even before second-line therapy, is considerable, and a straightforward oral regimen is not a trivial advantage.
The 60% reduction in death risk recorded in the trial, now confirmed by the FDA’s accelerated review, represents the clearest evidence yet that KRAS, once dismissed as an undruggable target, can be stopped. Revolution Medicines has announced the ASCO plenary presentation data as the basis for the approval, and the daraxonrasib pancreatic cancer approval sets a new benchmark for what second-line treatment in this disease can achieve.
